SCHEMBL1506130

SCHEMBL1506130

Cc1cc(-n2nc(Nc3ccc4c(c3)OC(F)(F)O4)cc2CC(=O)NC2CCC2)ccn1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MAPK1 P28482 10/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ KIT P10721 1/20 0.39
▸ BRAF P15056 1/20 0.39
▸ SMYD3 Q9H7B4 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ ADORA2B P29275 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ TGFBR1 P36897 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1506374 0.97 KIT (0.41) RECQLSMN1; SMN2MAPK1CYP1A2KIT
SCHEMBL10009662 0.88 CYP1A2 (0.42) RECQLSMN1; SMN2MAPK1CYP1A2KIT
SCHEMBL10010643 0.88 MAPK1 (0.40) RECQLSMN1; SMN2MAPK1CYP1A2KIT
SCHEMBL10009318 0.86 BRAF (0.42) MAPK1CYP1A2KITBRAFADORA3
SCHEMBL1506086 0.85 CYP1A2 (0.42) MAPK1CYP1A2KITBRAFADORA3
SCHEMBL1506162 0.82 CYP1A2 (0.40) MAPK1CYP1A2KITBRAFADORA3
SCHEMBL1506199 0.82 CYP1A2 (0.41) MAPK1CYP1A2KITBRAFADORA3
SCHEMBL1506317 0.80 BRAF (0.38) MAPK1CYP1A2KITBRAFADORA3
SCHEMBL1506277 0.80 CYP1A2 (0.39) MAPK1CYP1A2KITBRAFADORA3
SCHEMBL10008365 0.79 MAPK1 (0.43) MAPK1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
EP-2491024-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES Janssen Pharmaceutica N.V. (BE) 2012-08-29 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed
WO-2011033018-A1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2011-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 RECQL 1210/4885SMN1; SMN2 1814/4885MAPK1 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback